Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30290947 | 1.00 | DTYMK (0.44) | DTYMKHPGDL3MBTL1HDAC1NAMPT | |
| SCHEMBL3655864 | 0.90 | HPGD (0.45) | HPGDL3MBTL1HDAC1NAMPTCYP1A2 | |
| SCHEMBL135312 | 0.89 | KMT2A (0.47) | HPGDL3MBTL1HDAC1NAMPTCYP1A2 | |
| SCHEMBL31305194 | 0.89 | KMT2A (0.47) | HPGDL3MBTL1HDAC1NAMPTCYP1A2 | |
| SCHEMBL8650394 | 0.84 | L3MBTL1 (0.42) | HPGDL3MBTL1HDAC1NAMPTCA1 | |
| SCHEMBL30910306 | 0.83 | NR1H4 (0.48) | L3MBTL1HDAC1NAMPTCA1CA2 | |
| SCHEMBL1205128 | 0.83 | NR1H4 (0.48) | L3MBTL1HDAC1NAMPTCA1CA2 | |
| SCHEMBL5718757 | 0.83 | ALDH1A1 (0.47) | HPGDCYP1A2CYP3A4CYP2C19KMT2A | |
| SCHEMBL3654154 | 0.82 | KMT2A (0.45) | HPGDL3MBTL1NAMPTCYP1A2CYP3A4 | |
| SCHEMBL30600397 | 0.82 | KMT2A (0.45) | HPGDL3MBTL1NAMPTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116023430-A | 2- (2- (2-benzoylamino) acetamide) benzoic acid derivative and preparation method and application thereof | 中国药科大学 | 2023-04-28 | — | — | CN | disclosed |
| US-20180118713-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2018-05-03 | — | — | US | disclosed |
| US-9834538-B2 | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170129873-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2017-05-11 | — | — | US | disclosed |
| US-9586929-B2 | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-03-07 | — | — | US | disclosed |
| EP-2205593-B1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI SA (FR) | 2016-01-13 | — | — | EP | disclosed |
| US-20150291555-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2015-10-15 | — | — | US | disclosed |
| US-9096573-B2 | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2015-08-04 | — | — | US | disclosed |
| CN-104211684-A | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORP | 2014-12-17 | — | — | CN | disclosed |
| EP-2416777-B1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI SA (FR) | 2014-11-12 | — | — | EP | disclosed |
| EP-2416777-A1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-02-15 | — | — | EP | disclosed |
| EP-2411009-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-02-01 | — | — | EP | disclosed |
| CN-101952272-A | 6-, 7-or 8-substituted quinazolinone derivatives, compositions containing the same, and methods of use thereof | CELGENE CORP | 2011-01-19 | — | — | CN | disclosed |
| WO-2010116090-A1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010109148-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| EP-2205593-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | Sanofi-Aventis (FR) | 2010-07-14 | — | — | EP | disclosed |
| EP-2200999-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009077680-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS (FR) | 2009-06-25 | — | — | WO | disclosed |
| US-20090093504-A1 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2009-04-09 | — | — | US | disclosed |
| WO-2009042177-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129873-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP2D6, CYP2B6 | DTYMK 1660/4885HPGD 518/4885L3MBTL1 4608/4885 |
| US-20090093504-A1 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CYP3A7, CYP2D6, CYP2B6 | DTYMK 1660/4885HPGD 518/4885L3MBTL1 4608/4885 |
| US-20180118713-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP2D6, CYP2B6 | DTYMK 1660/4885HPGD 518/4885L3MBTL1 4608/4885 |
| US-20150291555-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP2D6, CYP2B6 | DTYMK 1660/4885HPGD 518/4885L3MBTL1 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.